Literature

Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman AL, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial:467–478.
Gélinas J-F, Azizi H, Kiesslich S, Lanthier S, Perdersen J, Chahal PS, Ansorge S, Kobinger G, Gilbert R, Kamen AA. 2019. Production of rVSV-ZEBOV in serum-free suspension culture of HEK 293SF cells.Vaccine 37 :6624–6632. https://linkinghub.elsevier.com/retrieve/pii/S0264410X19312538.
Gélinas J, Kiesslich S, Gilbert R, Kamen AA. 2020. Titration methods for rVSV-based vaccine manufacturing. MethodsX 7 .
Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, Carroll MW, Dean NE, Diatta I, Doumbia M, Draguez B, Duraffour S, Enwere G, Grais R, Gunther S, Gsell P-S, Hossmann S, Watle SV, Kondé MK, Kéïta S, Kone S, Kuisma E, Levine MM, Mandal S, Mauget T, Norheim G, Riveros X, Soumah A, Trelle S, Vicari AS, Røttingen J-A, Kieny M-P. 2017. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).Lancet 389 :505–518. http://www.sciencedirect.com/science/article/pii/S0140673616326216.
Kiesslich S, Kamen AA. 2020. Vero cell upstream bioprocess development for the production of viral vectors and vaccines. Biotechnol. Adv. 44 . https://doi.org/10.1016/j.biotechadv.2020.107608.
Kiesslich S, Losa JPV, Gélinas J, Kamen AA. 2020. Serum-free production of rVSV-ZEBOV in Vero cells: Microcarrier bioreactor versus scale-XTM hydro fixed-bed. J. Biotechnol.310 :32–39. https://doi.org/10.1016/j.jbiotec.2020.01.015.
Kim GN, Wu K, Hong JP, Awamleh Z, Kang CY. 2015. Creation of Matrix Protein Gene Variants of Two Serotypes of Vesicular Stomatitis Virus as Prime-Boost Vaccine Vectors. J. Virol. 89 :6338–6351.
Lichty BD, Power AT, Stojdl DF, Bell JC. 2004. Vesicular stomatitis virus: Re-inventing the bullet. Trends Mol. Med.10 :210–216.
Litwin J. 1992. The growth of Vero cells as suspended aggregates in serum-free medium. Anim. Cell Technol. Butterworth-Heinemann 414–417 p. http://dx.doi.org/10.1016/B978-0-7506-0421-5.50096-9.
Mangion M, Gélinas JF, Bakhshi Zadeh Gashti A, Azizi H, Kiesslich S, Nassoury N, Chahal PS, Kobinger G, Gilbert R, Garnier A, Gaillet B, Kamen A, Bakhshi A, Gashti Z, Azizi H, Kiesslich S, Nassoury N, Chahal PS, Kobinger G, Gilbert R, Garnier A, Gaillet B, Kamen A. 2020. Evaluation of novel HIV vaccine candidates using recombinant vesicular stomatitis virus vector produced in serum-free Vero cell cultures.Vaccine 38 :7949–7955. https://doi.org/10.1016/j.vaccine.2020.10.058.
Monath TP, Fast PE, Modjarrad K, Clarke DK, Martin BK, Fusco J, Nichols R, Heppner DG, Simon JK, Dubey S, Troth SP, Wolf J, Singh V, Coller B-AA, Robertson JS, Gray Heppner D, Simon JK, Dubey S, Troth SP, Wolf J, Singh V, Coller B-AA, Robertson JS. 2019. rVSVΔG-ZEBOV-GP (also designated V920) Recombinant Vesicular Stomatitis Virus Pseudotyped with Ebola Zaire Glycoprotein: Standardized Template with Key Considerations for a Risk/Benefit Assessment. Vaccine X 1 . https://doi.org/10.1016/j.jvacx.2019.100009.
Munis AM, Bentley EM, Takeuchi Y. 2020. A tool with many applications: vesicular stomatitis virus in research and medicine. Expert Opin. Biol. Ther. 00 :1–15. https://doi.org/10.1080/14712598.2020.1787981.
Paillet C, Forno G, Kratje R, Etcheverrigaray M. 2009. Suspension-Vero cell cultures as a platform for viral vaccine production. Vaccine27 :6464–6467.
Quesney S, Marc A, Gerdil C, Gimenez C, Marvel J, Richard Y, Meignier B. 2003. Kinetics and metabolic specificities of Vero cells in bioreactor cultures with serum-free medium. Cytotechnology42 :1–11.
Robison CS, Whitt MA. 2000. The Membrane-Proximal Stem Region of Vesicular Stomatitis Virus G Protein Confers Efficient Virus Assembly.J. Virol. 74 :2239–2246.
Rourou S, Ben Zakkour M, Kallel H. 2019. Adaptation of Vero cells to suspension growth for rabies virus production in different serum free media. Vaccine 37 :6987–6995. https://doi.org/10.1016/j.vaccine.2019.05.092.
Shen CF, Guilbault C, Li X, Elahi SM, Ansorge S, Kamen AA, Gilbert R. 2019. Development of suspension adapted Vero cell culture process technology for production of viral vaccines. Vaccine37 :6996–7002. https://doi.org/10.1016/j.vaccine.2019.07.003.
Ura T, Yamashita A, Mizuki N, Okuda K, Shimada M. 2020. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.Vaccine . https://doi.org/10.1016/j.vaccine.2020.11.054.
World Health Organization. 2020. DRAFT landscape of COVID-19 candidate vaccines - 19 October. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.